Search JIM Advanced Search

Journal of Chinese Integrative Medicine ›› 2007, Vol. 5 ›› Issue (1): 85-91.doi: 10.3736/jcim20070118

• Literature Review • Previous Articles     Next Articles

Progress of treatment for bladder cancer

Zhi-cheng Cao   

  1. Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong SAR, ChinaAbstract
  • Online:2007-01-31 Published:2007-01-21

Key words: bladder neoplasms, integrated traditional and Western medicine, therapeutics, review

[1] Parkin DM, Bray F, Ferlay J , et al. Global cancer statistics, 2002[J]. CA Cancer J Clin, 2005,55(2):74-108
[2] Carreon T, LeMasters GK, Ruder AM , et al.The genetic and environmental factors involved in benzidine metabolism and bladder carcinogenesis in exposed workers[J].Front Biosci, 2006, 11 2889-2902
[3] Riedel K, Scherer G, Engl J , et al. Determination of three carcinogenic aromatic amines in urine of smokers and nonsmokers[J]. J Anal Toxicol, 2006,30(3):187-195
doi: 10.1109/96.544365 pmid: 16803653
[4] Samanic C, Kogevinas M, Dosemeci M , et al. Smoking and bladder cancer in Spain: effects of tobacco type, timing, environmental tobacco smoke, and gender[J]. Cancer Epidemiol Biomarkers Prev, 2006,15(7):1348-1354
[5] Lin J, Spitz MR, Dinney CP , et al. Bladder cancer risk as modified by family history and smoking[J]. Cancer, 2006,107(4):705-711
doi: 10.1002/cncr.22071 pmid: 16845665
[6] Sidransky H . Tryptophan and carcinogenesis: review and update on how tryptophan may act[J]. Nutr Cancer, 1997,29(3):181-194
doi: 10.1080/01635589709514623 pmid: 9457738
[7] Badawi AF, Mostafa MH, Probert A , et al. Role of schistosomiasis in human bladder cancer: evidence of association, aetiological factors, and basic mechanisms of carcinogenesis[J]. Eur J Cancer Prev, 1995,4(1):45-59
[8] Pelucchi C, Bosetti C, Negri E , et al. Mechanisms of disease: The epidemiology of bladder cancer[J]. Nat Clin Pract Urol, 2006,3(6):327-340
doi: 10.1038/ncpuro0510 pmid: 16763645
[9] Kim WJ, Quan C . Genetic and epigenetic aspects of bladder cancer[J]. J Cell Biochem, 2005,95(1):24-33
doi: 10.1002/jcb.20412 pmid: 15759278
[10] Coogan CL, Estrada CR, Kapur S , et al. HER-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder[J]. Urology, 2004,63(4):786-790
doi: 10.1016/j.urology.2003.10.040
[11] Hirao S, Hirao T, Marsit CJ , et al. Loss of heterozygosity on chromosome 9q and p53 alterations in human bladder cancer[J]. Cancer, 2005,104(9):1918-1923
doi: 10.1002/cncr.21423 pmid: 16149093
[12] Tuziak T, Jeong J, Majewski T , et al. High-resolution whole-organ mapping with SNPs and its significance to early events of carcinogenesis[J]. Lab Invest, 2005,85(5):689-701
[13] Bernard-Pierrot I, Brams A, Dunois-Larde C , et al. Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b[J]. Carcinogenesis, 2006,27(4):740-747
doi: 10.1093/carcin/bgi290 pmid: 16338952
[14] Lindgren D, Liedberg F, Andersson A , et al. Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q[J]. Oncogene, 2006,25(18):2685-2696
[15] Beecken WD, Engl T, Engels K , et al. Clinical relevance of maspin expression in bladder cancer[J]. World J Urol, 2006,24(3):338-344
doi: 10.1007/s00345-006-0085-z pmid: 16832651
[16] Ohlsson G, Moreira JM, Gromov P , et al. Loss of expression of the adipocyte-type fatty acid-binding protein(A-FABP) is associated with progression of human urothelial carcinomas[J]. Mol Cell Proteomics, 2005,4(4):570-581
[17] Brown FM . Urine cytology. It is still the gold standard for screening?[J]. Urol Clin North Am, 2000,27(1):25-37
doi: 10.1016/S0094-0143(05)70231-7 pmid: 10696242
[18] Bassi P, De Marco V, De Lisa A , et al. Non-invasive diagnostic tests for bladder cancer: a review of the literature[J]. Urol Int, 2005,75(3):193-200
[19] Drieskens O, Oyen R, Van Poppel H , et al. FDG-PET for preoperative staging of bladder cancer[J]. Eur J Nucl Med Mol Imaging, 2005,32(12):1412-1417
doi: 10.1007/s00259-005-1886-9 pmid: 16133380
[20] Picchio M, Treiber U, Beer AJ , et al. Value of 11C-choline PET and contrast-enhanced CT for staging of bladder cancer: correlation with histopathologic findings[J]. J Nucl Med, 2006,47(6):938-944
[21] Rodgers M, Nixon J, Hempel S , et al. Diagnostic tests and algorithms used in the investigation of haematuria: systematic reviews and economic evaluation[J].Health Technol Assess 2006, 10(18):iii-iv, xi-259
[22] Celis JE, Gromova I, Moreira JM , et al. Impact of proteomics on bladder cancer research[J]. Pharmacogenomics, 2004,5(4):381-394
doi: 10.1517/14622416.5.4.381 pmid: 15165174
[23] 曹志成, 余坚文, 梁荣能 . 蛋白质组学——引领后基因组时代[J]. 中国生物工程杂志, 2005,25(1):33-38
Cho CS, Yue KM , Leung WN.Proteomics--Leading the Postgenome Era[J].Zhongguo Sheng Wu Gong Cheng Za Zhi, 2005, 25(1):33-38. Chinese with abstract in English
[24] O'Riordan E , Goligorsky MS.Emerging studies of the urinary proteome: the end of the beginning?[J]. Curr Opin Nephrol Hypertens, 2005,14(6):579-585
[25] Konety BR . Molecular markers in bladder cancer: A critical appraisal[J]. Urol Oncol, 2006,24(4):326-337
doi: 10.1016/j.urolonc.2005.11.023 pmid: 16818187
[26] Liu BC, Ehrlich JR . Proteomics approaches to urologic diseases[J]. Expert Rev Proteomics, 2006,3(3):283-296
doi: 10.1586/14789450.3.3.283 pmid: 16771701
[27] Pisitkun T, Johnstone R, Knepper MA . Discovery of urinary biomarkers[J]. Mol Cell Proteomics, 2006,5(10):1760-1771
[28] Hoque MO, Begum S, Topaloglu O , et al. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection[J]. J Natl Cancer Inst, 2006,98(14):996-1004
doi: 10.1093/jnci/djj265 pmid: 16849682
[29] Osman I, Bajorin DF, Sun TT , et al. Novel blood biomarkers of human urinary bladder cancer[J]. Clin Cancer Res, 2006,12(11 Pt 1):3374-3380
doi: 10.1016/j.urolonc.2006.08.017 pmid: 16740760
[30] Feil G, Stenzl A . Tumor marker tests in bladder cancer[J]. Actas Urol Esp, 2006,30(1):38-45
doi: 10.4321/S0210-48062006000100006 pmid: 16703728
[31] Grossman HB, Messing E, Soloway M , et al. Detection of bladder cancer using a point-of-care proteomic assay[J]. JAMA, 2005,293(7):810-816
doi: 10.1001/jama.293.20.2467-a pmid: 15914744
[32] Svatek RS, Sagalowsky AI, Lotan Y . Economic impact of screening for bladder cancer using bladder tumor markers: A decision analysis[J]. Urol Oncol, 2006,24(4):338-343
[33] Akhtar M, Gallagher L, Rohan S . Survivin: role in diagnosis, prognosis, and treatment of bladder cancer[J]. Adv Anat Pathol, 2006,13(3):122-126
doi: 10.1097/00125480-200605000-00003 pmid: 16778475
[34] Sanchez-Carbayo M, Socci ND, Lozano JJ , et al. Profiling bladder cancer using targeted antibody arrays[J]. Am J Pathol, 2006,168(1):93-103
doi: 10.2353/ajpath.2006.050601 pmid: 16400012
[35] Stejskal D, Fiala RR . Evaluation of serum and urine clusterin as a potential tumor marker for urinary bladder cancer[J]. Neoplasma, 2006,53(4):343-346
pmid: 16830064
[36] Iwaki H, Kageyama S, Isono T , et al. Diagnostic potential in bladder cancer of a panel of tumor markers(calreticulin, gamma-synuclein, and catechol-o-methyltransferase) identified by proteomic analysis[J]. Cancer Sci, 2004,95(12):955-961
[37] Moreira JM, Gromov P, Celis JE . Expression of the tumor suppressor protein 14-3-3 sigma is down-regulated in invasive transitional cell carcinomas of the urinary bladder undergoing epithelial-to-mesenchymal transition[J]. Mol Cell Proteomics, 2004,3(4):410-419
[38] Vlahou A, Schellhammer PF, Mendrinos S , et al. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine[J]. Am J Pathol, 2001,158(4):1491-1502
[39] Lin CY, Tsui KH, Yu CC , et al. Searching cell-secreted proteomes for potential urinary bladder tumor markers[J]. Proteomics, 2006,6(15):4381-4389
doi: 10.1002/pmic.200600066 pmid: 16819731
[40] Wulfing C, Eltze E, Von Struensee D , et al. Cyclooxygenase-2-expression in bladder cancer: tumor-biological and clinical implications[J]. Aktuelle Urol, 2004,35(4):331-338
doi: 10.1055/s-2004-818537 pmid: 15459875
[41] Fradet Y, Picard V, Bergeron A , et al. Cancer-testis antigen expression in bladder cancer[J]. Prog Urol, 2005,15(6 Suppl 1):1303-1313
doi: 10.1007/s00467-006-0193-4 pmid: 17069033
[42] Wulfing C, Eltze E, Piechota H , et al. Expression of endothelin-1 and endothelin-A and -B receptors in invasive bladder cancer[J]. Oncol Rep, 2005,13(2):223-228
[43] Xia G, Kumar SR, Hawes D , et al. Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer[J]. J Urol., 2006,175(4):1245-1252
doi: 10.1016/S0022-5347(05)00736-6 pmid: 16515971
[44] 曹志成 . 医疗新趋势——个体医疗[J].大众医学, 2004, 10 74-75
[45] Boccardo F , almeri L. Adjuvant chemotherapy of bladder cancer[J].Ann Oncol, 2006, 17 Suppl 5 v129-v132
doi: 10.1093/annonc/mdj967 pmid: 16807440
[46] Kaufman DS . Challenges in the treatment of bladder cancer[J]. Ann Oncol, 2006,17(Suppl 5):v106-v112
doi: 10.1093/annonc/mdj963 pmid: 16807436
[47] Oosterlinck W . Guidelines on diagnosis and treatment of superficial bladder cancer[J]. Minerva Urol Nefrol, 2004,56(1):65-72
pmid: 15195031
[48] Fokdal L , Hoyer M, von der Maase H . Radical radiotherapy for urinary bladder cancer: treatment outcomes[J]. Expert Rev Anticancer Ther, 2006,6(2):269-279
doi: 10.1586/14737140.6.2.269 pmid: 16445379
[49] Winquist E.Perioperative chemotherapy for localized bladder cancer[J].Can J Urol, 2006, 13 Suppl 1 77-80
[50] Garcia JA, Dreicer R . Adjuvant and neoadjuvant chemotherapy for bladder cancer: management and controversies[J]. Nat Clin Pract Urol, 2005,2(1):32-37
[51] Sternberg CN, Calabro F . Adjuvant chemotherapy for bladder cancer[J]. Expert Rev Anticancer Ther, 2005,5(6):987-992
[52] Mambrini A, Fiorentini G, Zamagni D , et al. Intra-arterial chemotherapy for invasive bladder cancer[J]. J Exp Clin Cancer Res, 2003,22(4 Suppl):21-23
doi: 10.1200/JCO.2003.10.925 pmid: 16767901
[53] Goebell PJ, Vom Dorp F, Rubben H . Value of systemic chemotherapy in bladder cancer[J]. Urologe A, 2006,45(5):586-593
doi: 10.1007/s00120-006-1058-y pmid: 16710678
[54] Bamias A, Dimopoulos MA . Neoadjuvant chemotherapy in invasive bladder cancer[J]. Expert Rev Anticancer Ther, 2005,5(6):993-1000
doi: 10.1038/bjc.1991.367 pmid: 1977623
[55] Roberts JT . Chemotherapy for metastatic bladder cancer[J]. Clin Oncol (R Coll Radiol), 2005,17(7):514-523
doi: 10.1016/j.clon.2005.07.007 pmid: 16238139
[56] Adorini L, Daniel KC, Penna G . Vitamin D receptor agonists, cancer and the immune system: an intricate relationship[J]. Curr Top Med Chem, 2006,6(12):1297-1301
doi: 10.2174/156802606777864890 pmid: 16848743
[57] Rosenberg JE, Carroll PR, Small EJ . Update on chemotherapy for advanced bladder cancer[J]. J Urol, 2005,174(1):14-20
doi: 10.1097/01.ju.0000162039.38023.5f pmid: 15947569
[58] Pagliaro LC, Sharma P . Review of metastatic bladder cancer[J]. Minerva Urol Nefrol, 2006,58(1):53-71
pmid: 16760884
[59] Roberts JT, von der Maase H, Sengelov L . et al. Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanc, 2006, 17 Suppl 5 v118-v122
[60] Siefker-Radtke A . Systemic chemotherapy options for metastatic bladder cancer[J]. Expert Rev Anticancer Ther, 2006,6(6):877-885
doi: 10.1586/14737140.6.6.877 pmid: 16761931
[61] Goebell PJ, Vom Dorp F, Rodel C , et al. Noninvasive and invasive bladder cancer: Diagnostics and treatment[J]. Urologe A, 2006,45(7):873-886
doi: 10.1007/s00120-006-1065-z pmid: 16791629
[62] Moskovitz B, Meyer G, Kravtzov A , et al. Thermo-chemotherapy for intermediate or high-risk recurrent superficial bladder cancer patients[J]. Ann Oncol, 2005,16(4):585-589
doi: 10.1093/annonc/mdi124 pmid: 15734775
[63] Muraro GB, Grifoni R , Spazzafumo L . Endoscopic therapy of superficial bladder cancer in high-risk patients: Holmium laser versus transurethral resection[J].Surg Technol Int, 2005,14 222-226
[64] Gwynn ES, Clark PE, Hall MC . Recent advances in the treatment of bladder cancer[J]. Expert Rev Anticancer Ther, 2005,5(6):1023-1030
doi: 10.1586/14737140.5.6.1023 pmid: 16336093
[65] 谢国材, 李捍东 . 常见肿瘤病防治(第1版)[M]. 广州: 广州出版社, 2003,( 第1版):107-110
Xie GC, Li HD. Prevention and treatment of common cancers(1st ed)[M]. Guangzhou: Guangzhou Press,2003,(1st ed):107-110. Chinese
[66] 陈世伟, 张利民 . 肿瘤中西医综合治疗(第1版)[M]. 北京: 人民卫生出版社, 2001,( 第1版):531-532
Chen SW, Zhang LM. Comprehensive treatment of tumor by traditional Chinese and Western medicine(1st ed)[M]. Beijing: People's Medical Publishing House,2001,(1st ed):531-532. Chinese
[67] 顾奎兴 . 中医肿瘤学(第1版)[M]. 南京: 东南大学出版社, 1998,( 第1版):127-129
Gu KX. Phymatology of traditional Chinese medicine(1st ed)[M]. Nanjing: Dongnan University Press,1998,(1st ed):127-129. Chinese
[68] 章永红 . 抗癌中药大全(第1版)[M]. 南京: 江苏科学技术出版社, 2000,( 第1版):34-425
Zhang YH. . Collection of anticancer traditional Chinese drugs(1st ed)[M]. Nanjing: Jiangsu Scientific and Technical Publishers,2000,(1st ed):34-425 2000,(1st ed):34-425. Chinese
[69] 吴玉生 . 常见肿瘤病中西医诊疗与调养(第1版)[M]. 广州: 广东旅游出版社, 2002,( 第1版):186-187
Wu YS. Diagnosis, treatment and nursing of common cancers by integrated traditional Chinese and Western medicine(1st ed)[M]. Guangzhou: Guangdong Tourism Press,2002,(1st ed):186-187. Chinese
[70] 周岱翰, 林丽珠 . 中医肿瘤食疗学(第1版)[M]. 贵阳: 贵州科学技术出版社, 2003,( 第1版):271-274
Zhou DH, Lin LZ.Phagotherapy of traditional Chinese medicine for tumor( 1st ed) [M].Guiyang: Guizhou Scientific and Technical Publishers , 2003,( 1st ed):271-274. Chinese
[71] 张代钊 . 中西医结合治疗放化疗毒副反应(第1版)[M]. 北京: 人民卫生出版社, 2000,( 第1版):283-308
Zhang DZ. Combined treatment of traditional Chinese and Western medicine for chemotherapeutic side reactions(1st ed)[M]. Beijing: People's Medical Publishing House,2000,(1st ed):283-308. Chinese
[72] 李岩, 王艳玲, 何其梅 . 肿瘤医护锦囊(第1版)[M]. 香港: 万里机构, 1997,( 第1版):203-204
Li Y, Wang YL, He QM.Collection of tumor treatments and nursing( 1st ed) [M].Hong Kong: Wanli Organization , 1997,( 1st ed):203-204. Chinese
[73] Adam L, Kassouf W , Dinney CP .Clinical applications for targeted therapy in bladder cancer [J].Urol Clin North Am, 2005, 32(2):239-246,vii
doi: 10.1016/j.ucl.2005.02.004 pmid: 15862621
[74] 曹志成 . 纳米医学[J]. 科学(上海), 2005,57(4):8-10
Cho CS.Nanomedicine[J].Ke Xue ( Shanghai), 2005, 57(4):8-10. Chinese
[75] Totterman TH, Loskog A, Essand M . The immunotherapy of prostate and bladder cancer[J]. BJU Int, 2005,96(5):728-735
doi: 10.1111/j.1464-410X.2005.05772.x pmid: 16144528
[76] Wang J, Liu XG, He CW , et al. Synergic anti-tumour effect of B7.1 gene modified tumour vaccine combined with allicin for murine bladder tumour[J]. Chin Med J (Engl), 2005,118(3):242-245
[77] Nagasawa J, Mizokami A, Koshida K , et al. Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo[J]. Int J Urol, 2006,13(5):587-592
[78] Baselga J . Targeting tyrosine kinases in cancer: the second wave[J]. Science, 2006,312(5777):1175-1178
doi: 10.1126/science.1125951 pmid: 16728632
[79] Cho HJ, Kim JK, Kim KD , et al. Upregulation of Bcl-2 is associated with cisplatin-resistance via inhibition of Bax translocation in human bladder cancer cells[J]. Cancer Lett, 2006,237(1):56-66
[80] Fuessel S, Herrmann J, Ning S , et al. Chemosensitization of bladder cancer cells by survivin-directed antisense oligodeoxynucleotides and siRNA[J]. Cancer Lett, 2006,232(2):243-254
[81] Nogawa M, Yuasa T, Kimura S , et al. Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer[J]. J Clin Invest, 2005,115(4):978-985
[82] Ding Y, Wang G, Ling MT , et al. Significance of Id-1 up-regulation and its association with EGFR in bladder cancer cell invasion[J]. Int J Oncol, 2006,28(4):847-854
[83] Xia G, Kumar SR, Stein JP , et al. EphB4 receptor tyrosine kinase is expressed in bladder cancer and provides signals for cell survival[J]. Oncogene, 2006,25(5):769-780
[84] Zou L, Zhang P, Luo C , et al. shRNA-targeted hTERT suppress cell proliferation of bladder cancer by inhibiting telomerase activity[J]. Cancer Chemother Pharmacol, 2006,57(3):328-334
[85] Horinaga M, Harsch KM, Fukuyama R , et al. Intravesical interleukin-12 gene therapy in an orthotopic bladder cancer model[J]. Urology, 2005,66(2):461-466
doi: 10.1016/j.urology.2005.03.052 pmid: 16040105
[86] Mullerad M, Bochner BH, Adusumilli PS , et al. Herpes simplex virus based gene therapy enhances the efficacy of mitomycin C for the treatment of human bladder transitional cell carcinoma[J]. J Urol, 2005,174(2):741-746
[87] Terao S, Shirakawa T, Goda K , et al. Recombinant interleukin-2 enhanced the antitumor effect of ADV/RSV-HSV-tk/ACV therapy in a murine bladder cancer model[J]. Anticancer Res, 2005,25(4):2757-2760
[88] Inoue M, Tomizawa K, Matsushita M , et al. p53 protein transduction therapy: successful targeting and inhibition of the growth of the bladder cancer cells[J]. Eur Urol, 2006,49(1):161-168
doi: 10.1016/j.eururo.2005.08.019
[89] Lu Z, Yeh TK, Tsai M , et al. Paclitaxel-loaded gelatin nanoparticles for intravesical bladder cancer therapy[J]. Clin Cancer Res, 2004,10(22):7677-7684
doi: 10.1016/j.juro.2010.11.091 pmid: 15570001
[90] 曹志成 . 癌症病人的中医药治疗与调理[J]. 中华医药杂志, 2005,5(9):925-928
Cho CS. Treatment and rehabilitation for cancer patients with Chinese medicine[J].Zhonghua Yi Yao Za Zhi, 2005, 5(9):925-928.Chinese with abstract in English
[91] Mazzucchelli R, Barbisan F, Tarquini LM , et al. Urothelial changes induced by therapeutic procedures for bladder cancer. A review[J]. Anal Quant Cytol Histol, 2005,27(1):27-34
doi: 10.1016/j.amjsurg.2005.10.031 pmid: 15794449
[92] Alonzi R, Hoskin P . Novel therapies in bladder cancer[J]. Clin Oncol (R Coll Radiol), 2005,17(7):524-538
doi: 10.1016/j.clon.2005.07.001 pmid: 16238140
[93] So A, Rocchi P, Gleave M . Antisense oligonucleotide therapy in the management of bladder cancer[J]. Curr Opin Urol, 2005,15(5):320-327
doi: 10.1021/om00007a004 pmid: 16093856
[94] O'Kane HF , Watson CJ, Johnston SR, et al.Targeting death receptors in bladder, prostate and renal cancer[J]. J Urol, 2006,175(2):432-438
[95] Palena C, Abrams SI, Schlom J, et al.Cancer vaccines: preclinical studies and novel strategies[J].Adv Cancer Res , 2006, 95 115-145
[96] Pollera CF, Nelli F . Developing innovative strategies for advanced transitional cell carcinoma of the bladder[J]. Expert Rev Anticancer Ther, 2006,6(1):83-92
doi: 10.1586/14737140.6.1.83 pmid: 16375647
[97] Shah JB, Badalato GM , McKiernan JM.New treatments for superficial bladder cancer[J]. Curr Oncol Rep, 2006,8(3):201-205
doi: 10.1007/s11912-006-0020-x
[1] Ming-min Xu, Pei Guo, Qing-yu Ma, Xuan Zhou, Yu-long Wei, Lu Wang, Yue Chen, Yu Guo. Can acupuncture enhance therapeutic effectiveness of antidepressants and reduce adverse drug reactions in patients with depression? A systematic review and meta-analysis. Journal of Integrative Medicine, 2022, 20(4): 305-320.
[2] Ting-ting Lu, Cun-cun Lu, Mei-xuan Li, Li-xin Ke, Hui Cai, Ke-hu Yang. Reporting and methodological quality of meta-analyses of acupuncture for patients with migraine: A methodological investigation with evidence map. Journal of Integrative Medicine, 2022, 20(3): 213-220.
[3] Witoo Dilokthornsakul, Ramanya Kosiyaporn, Rattanamanee Wuttipongwaragon, Piyameth Dilokthornsakul. Potential effects of propolis and honey in COVID-19 prevention and treatment: A systematic review of in silico and clinical studies. Journal of Integrative Medicine, 2022, 20(2): 114-125.
[4] Jun-peng Yao, Li-ping Chen, Xian-jun Xiao, Ting-hui Hou, Si-yuan Zhou, Ming-min Xu, Kai Wang, Yu-jun Hou, Lin Zhang, Ying Li. Effectiveness and safety of acupuncture for treating functional constipation: An overview of systematic reviews. Journal of Integrative Medicine, 2022, 20(1): 13-25.
[5] Yi Yuan, Rui-Ting Wang, Jun Xia, Hui-Juan Cao. Interventions for preventing influenza: an overview of Cochrane systematic reviews and a Bayesian network meta-analysis. Journal of Integrative Medicine, 2021, 19(6): 503-514.
[6] Meng-zhu Zhao, Chen Zhao, Shuang-shuang Tu, Xu-xu Wei, Hong-cai Shang. Evaluating the methodology of studies conducted during the global COVID-19 pandemic: A systematic review of randomized controlled trials. Journal of Integrative Medicine, 2021, 19(4): 317-326.
[7] Liang Dai, Ka Kei Chan, Jian-chun Mao, Yu Tian, Jun-hua Gu, Jun Zhou, Linda L.D. Zhong. Modified Zhibai Dihuang pill, a traditional Chinese medicine formula, on steroid withdrawal in systemic lupus erythematosus: A systematic review and meta-analysis. Journal of Integrative Medicine, 2020, 18(6): 478-491.
[8] Arthur Yin Fan, Sherman Gu, Sarah Faggert Alemi, Research Group for Evidence-based Chinese Medicine. Chinese herbal medicine for COVID-19: Current evidence with systematic review and meta-analysis. Journal of Integrative Medicine, 2020, 18(5): 385-394.
[9] Xian-jun Xiao, Lei-xiao Zhang, Yun-zhou Shi, Jun-peng Yao, Wei Cao, Ying Liu, Zi-hao Zou, Si-yuan Zhou, Ming-ling Chen, Chun-xiao Li, Qian-hua Zheng, Ying Li. Cupping therapy for patients with chronic urticaria: A systematic review and meta-analysis. Journal of Integrative Medicine, 2020, 18(4): 303-312.
[10] Dong-dong Yu, Liang-zhen You, Wan-qiu Huang, Hui Cao, Fan-jing Wang, Xiu-qin Tang, Zhao-hui Fang, Guo-ming Shen, Yu-xiang Guan. Effects of traditional Chinese exercises on blood glucose and hemoglobin A1c levels in patients with prediabetes: A systematic review and meta-analysis. Journal of Integrative Medicine, 2020, 18(4): 292-302.
[11] Dona Nirmani Ann Wijewickrama Samarakoon, Deepthi Inoka Uluwaduge, Malith Aravinda Siriwardhene. Mechanisms of action of Sri Lankan herbal medicines used in the treatment of diabetes: A review. Journal of Integrative Medicine, 2020, 18(1): 13-20.
[12] Lena Grönblom Lundström, Ulrika Aasa, Yan Zhang, Tobias Sundberg. Health care in light of different theories of health—A proposed framework for integrating a social humanistic perspective into health care. Journal of Integrative Medicine, 2019, 17(5): 321-327.
[13] Jia Xu, Fu-qing Zhang, Jian Pei, Jun Ji . Acupuncture for migraine without aura: A systematic review and meta-analysis. Journal of Integrative Medicine, 2018, 16(5): 312-321.
[14] Wen-jie Xu, Ling-tai Wang, Zhi-ping Zhao, Li-ming Zhu, Liang-hua Zu, Qi Zhang, Dan-bo Dou. Prospects of a comprehensive evaluation system for traditional Chinese medicine services. Journal of Integrative Medicine, 2017, 15(6): 426-432.
[15] Naseem Akhtar Qureshi, Gazzaffi Ibrahim Ali, Tamer Shaban Abushanab, Ahmed Tawfik El-Olemy, Meshari Saleh Alqaed, Ibrahim S. El-Subai, Abdullah M.N. Al-Bedah. History of cupping (Hijama): A narrative review of literature. Journal of Integrative Medicine, 2017, 15(3): 172-181.
Full text



[1] Dong Yang, Yong-ping Du, Qing Shen, Wei Chen, Yan Yu, Guang-lei Chen. Expression of alpha-smooth muscle actin in renal tubulointerstitium in patients with kidney collateral stasis. Journal of Chinese Integrative Medicine, 2008, 6(1): 41-44
[2] Hai-feng Wei, Bai-liu Ya, Ling Zhao, Cui-fei Ye, Li Zhang, Lin Li. Evaluation of tongue manifestation of blood stasis syndrome and its relationship with blood rheological disorder in a rat model of transient brain ischemia. Journal of Chinese Integrative Medicine, 2008, 6(1): 73-76
[3] Xi Lin, Jian-ping Liu. Herbal medicines for viral myocarditis. Journal of Chinese Integrative Medicine, 2008, 6(1): 76
[4] Xi Lin, Jian-ping Liu. Tai chi for treating rheumatoid arthritis. Journal of Chinese Integrative Medicine, 2008, 6(1): 82
[5] Yan-bo Zhu , Qi Wang, Cheng-yu Wu, Guo-ming Pang, Jian-xiong Zhao, Shi-lin Shen, Zhong-yuan Xia , Xue Yan . Logistic regression analysis on relationships between traditional Chinese medicine constitutional types and overweight or obesity. Journal of Chinese Integrative Medicine, 2010, 8(11): 1023-1035
[6] Wei Xu, Meng Shi, Jian-gang Liu, Cheng-long Wang . Collagen protein expressions in ischemic myocardium of rats with acute myocardial infarction and effects of qi-tonifying, yin-tonifying and blood-activating herbs and detoxifying and blood-activating herbs. Journal of Chinese Integrative Medicine, 2010, 8(11): 1041-1047
[7] Tao Wang , Feng Qin. Effects of Chinese herbal medicine Xiaoyao Powder on monoamine neurotransmitters in hippocampus of rats with postpartum depression. Journal of Chinese Integrative Medicine, 2010, 8(11): 1075-1079
[8] Ying Xu , Chang-chun Zeng , Xiu-yu Cai , Rong-ping Guo , Guang Nie , Ying Jin. Chromaticity and optical spectrum colorimetry of the tongue color in different syndromes of primary hepatic carcinoma. Journal of Chinese Integrative Medicine, 2012, 10(11): 1263-1271
[9] Xiang-ying Mao , Qin Bian , Zi-yin Shen. Analysis of the osteogenetic effects exerted on mesenchymal stem cell strain C3H10T1/2 by icariin via MAPK signaling pathway in vitro. Journal of Chinese Integrative Medicine, 2012, 10(11): 1272-1278
[10] Samadder Asmita, Das Jayeeta, Das Sreemanti, Biswas Raktim, Rahman Khuda-Bukhsh Anisur. Ameliorative potentials of Syzygium jambolanum extract against arsenic-induced stress in L6 cells in vitro. Journal of Chinese Integrative Medicine, 2012, 10(11): 1293-1302